Reward Mechanisms in Obesity
- Sponsor
- Zoltan Pataky
- Study ID
- NCT03347890
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo — DRUGPatients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
Study Details
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes). According to the study protocol, 70 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector. All participants will first undergo a functional Magnetic Resonance Imaging (fMRI) session while being presented with gustatory stimuli. Second, participants will complete behavioural tasks (i.e., liking versus wanting, in the scanner) and questionnaires aiming at teasing apart reward mechanisms and emotional skills (e.g., emotional regulation ability) associated with food intake. Third, metabolic parameters and hormones involved in appetite regulation will be assessed and studied in relation to fMRI. These measurements will be repeated after 16 weeks in obese individuals. The control group of normal body weight individuals will be evaluated once at Baseline.
Key Dates
- Start date
- Mar 5, 2018
- Status verified
- Apr 2021
- Primary completion
- Mar 18, 2020
- Completion
- Mar 30, 2020
Study Design
- Enrollment
- 70 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Liraglutide 3.0 mg35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
- Placebo Comparator: Placebo35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
Primary Outcome Measure
Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system [ Time Frame: 16 weeks ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia